Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial

Teresa Maria Rosaria Noviello, Anna Maria Di Giacomo, Francesca Pia Caruso, Alessia Covre, Roberta Mortarini, Giovanni Scala, Maria Claudia Costa, Sandra Coral, Wolf H. Fridman, Catherine Sautès-Fridman, Silvia Brich, Giancarlo Pruneri, Elena Simonetti, Maria Fortunata Lofiego, Rossella Tufano, Davide Bedognetti, Andrea Anichini, Michele Maio, Michele Ceccarelli

Open source

DOI: 10.1038/s41467-023-40994-4
Published: 2023-09-22
Container: Nature Communications
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-023-40994-4,
  title = {Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial},
  author = {Teresa Maria Rosaria Noviello and Anna Maria Di Giacomo and Francesca Pia Caruso and Alessia Covre and Roberta Mortarini and Giovanni Scala and Maria Claudia Costa and Sandra Coral and Wolf H. Fridman and Catherine Sautès-Fridman and Silvia Brich and Giancarlo Pruneri and Elena Simonetti and Maria Fortunata Lofiego and Rossella Tufano and Davide Bedognetti and Andrea Anichini and Michele Maio and Michele Ceccarelli},
  year = {2023},
  journal = {Nature Communications},
  doi = {10.1038/s41467-023-40994-4},
  url = {https://doi.org/10.1038/s41467-023-40994-4}
}

RIS

TY  - JOUR
TI  - Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
AU  - Teresa Maria Rosaria Noviello
AU  - Anna Maria Di Giacomo
AU  - Francesca Pia Caruso
AU  - Alessia Covre
AU  - Roberta Mortarini
AU  - Giovanni Scala
AU  - Maria Claudia Costa
AU  - Sandra Coral
AU  - Wolf H. Fridman
AU  - Catherine Sautès-Fridman
AU  - Silvia Brich
AU  - Giancarlo Pruneri
AU  - Elena Simonetti
AU  - Maria Fortunata Lofiego
AU  - Rossella Tufano
AU  - Davide Bedognetti
AU  - Andrea Anichini
AU  - Michele Maio
AU  - Michele Ceccarelli
PY  - 2023
JO  - Nature Communications
DO  - 10.1038/s41467-023-40994-4
UR  - https://doi.org/10.1038/s41467-023-40994-4
ER  -

APA

Noviello, T. M. R., Giacomo, A. M. D., Caruso, F. P., Covre, A., Mortarini, R., Scala, G., Costa, M. C., Coral, S., Fridman, W. H., Sautès-Fridman, C., Brich, S., Pruneri, G., Simonetti, E., Lofiego, M. F., Tufano, R., Bedognetti, D., Anichini, A., Maio, M., & Ceccarelli, M. (2023). Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial. Nature Communications. https://doi.org/10.1038/s41467-023-40994-4

Source records

crossref · retrieved 2026-09-26T18:05:42.989Z